Clinical trial
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00470054 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00470054 |
|---|---|
| Title | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer |
| Official title | A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 44 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Apr 1, 2013 |
| First posted | May 7, 2007 |
| Last update posted | May 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: